Dr. Dolly (Ness) Tyan is a Professor of Pathology and a Director of the Stanford University Histocompatibility, Immunogenetics & Disease Profiling Laboratory. She has been active in histocompatibility since 1972 and trained with Rose Payne and Carl Grumet. She served as President of the American Society for Histocompatibility and Immunogenetics in 2001, on the Board and various committees of UNOS, and the Histocompatibility committee of the NMDP. She is Chair of the national UNOS/OPTN Histocompatibility Committee. Her presentation to the UNOS Board was fundamental to the implementation of the virtual crossmatching policy now in place nationally. She was an invited member of the international consensus conference in May, 2012, on testing and clinical management associated with antibodies in transplantation. Her career has focused on antibody characterization as it relates to transplantation as well as definition of HLA and KIR genes. From her first publications on antibody production in vitro in the early 1970s and DR epitope definition using monoclonal antibodies in 1980, she has continued to define new serologic specificities. Most recently her studies have focused on the definition of clinically relevant HLA antibodies and their antigen/allele targets. Her specialty area of expertise is the use of IVIG to down regulate antibody production in highly sensitized patients and characterization of residual antibody for determination of optimal time to transplant or reversal of antibody mediated rejection. She is co-inventor of the IVIG therapy for treatment of highly HLA sensitized patients both before and after transplant and is also co-inventor of the C1q assay for determination of clinically relevant complement fixing HLA antibody using single antigen beads. She is deeply immersed in NGS for HLA genomic definition with a goal of defining the epitope targets of donor specific antibody. Her clinical responsibilities include directing a comprehensive histocompatibility laboratory of 55 FTEs servicing 9 different solid organ and bone marrow/stem cell transplant programs at Stanford.